The Drug-Induced Respiratory Disease Website
Can be steroid-refractory (PMID 30176946, 30301729, 30837232)), requiring additional immunosuppression/modulation with e.g. IVIG, infliximab, or MMF. The development of ICPI-related ILD may negatively impact the outcome in lung cancer patients
Publications
Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Brahmer JR, Feller-Kopman D, Lerner AD, Lee H, Yarmus L, D'Alessio F, Hales RK, Lin CT, Psoter KJ, Danoff SK, Naidoo J
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 Dec;13;1930-1939 — 2018 Dec — 1930-1939
Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.
Cancer treatment and research communications 2018;15;17-20 — 2018 — 17-20
Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier AC, Tomasini P, Dansin E, Pérol M, Campana M, Gautschi O, Früh M, Fumet JD, Audigier-Valette C, Couraud S, Dalle S, Le
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.
The European respiratory journal 2017 08;50; — 2017 08
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Chest 2017 08;152;271-281 — 2017 08 — 271-281
Severe acute respiratory distress syndrome due to ipilimumab.
The European respiratory journal 2013 Sep;42;866-8 — 2013 Sep — 866-8